Analysts forecast that Champions Oncology Inc (NASDAQ:CSBR) will announce $7.83 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Champions Oncology’s earnings, with the lowest sales estimate coming in at $7.45 million and the highest estimate coming in at $8.20 million. Champions Oncology reported sales of $6.69 million during the same quarter last year, which would suggest a positive year over year growth rate of 17%. The firm is expected to issue its next quarterly earnings results on Monday, December 16th.
According to Zacks, analysts expect that Champions Oncology will report full year sales of $32.71 million for the current fiscal year, with estimates ranging from $32.42 million to $33.00 million. For the next fiscal year, analysts forecast that the firm will report sales of $40.32 million, with estimates ranging from $40.00 million to $40.64 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Champions Oncology.
Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings results on Monday, September 16th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.09). The firm had revenue of $6.74 million during the quarter, compared to analyst estimates of $7.50 million. Champions Oncology had a negative return on equity of 48.07% and a negative net margin of 3.61%.
Shares of CSBR traded down $0.04 on Thursday, reaching $5.26. The stock had a trading volume of 27,400 shares, compared to its average volume of 41,816. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 2.06. The firm has a market capitalization of $61.00 million, a PE ratio of 526.00 and a beta of 1.15. The firm has a 50-day moving average of $5.72 and a 200 day moving average of $7.15. Champions Oncology has a twelve month low of $5.01 and a twelve month high of $14.04.
Large investors have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new position in Champions Oncology in the first quarter valued at about $99,000. Susquehanna International Group LLP raised its position in Champions Oncology by 51.0% in the second quarter. Susquehanna International Group LLP now owns 24,510 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 8,279 shares during the period. Wedge Capital Management L L P NC purchased a new position in Champions Oncology in the second quarter valued at about $277,000. Alambic Investment Management L.P. raised its position in Champions Oncology by 27.0% in the second quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock valued at $538,000 after purchasing an additional 14,614 shares during the period. Finally, Tocqueville Asset Management L.P. grew its stake in shares of Champions Oncology by 69.1% during the third quarter. Tocqueville Asset Management L.P. now owns 134,568 shares of the biotechnology company’s stock valued at $760,000 after acquiring an additional 55,000 shares in the last quarter. 51.62% of the stock is currently owned by institutional investors.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Featured Story: What Does Beta Mean In Stock Selection?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.